What is HC Wainwright’s Estimate for BiomX FY2025 Earnings?

BiomX Inc. (NYSEAMERICAN:PHGE) – Investment analysts at HC Wainwright upped their FY2025 EPS estimates for BiomX in a research report issued on Tuesday, November 25th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($19.80) per share for the year, up from their prior estimate of ($22.43). HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for BiomX’s current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for BiomX’s Q4 2025 earnings at ($4.61) EPS, FY2026 earnings at ($5.85) EPS, FY2027 earnings at ($6.01) EPS and FY2028 earnings at ($4.57) EPS.

BiomX Stock Down 7.2%

NYSEAMERICAN PHGE opened at $4.36 on Thursday. The firm has a market cap of $6.67 million, a P/E ratio of -0.17 and a beta of 1.46. BiomX has a 52-week low of $4.10 and a 52-week high of $22.06. The business’s 50-day moving average price is $8.92 and its 200 day moving average price is $9.09.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).